Kidney Cancer

Immunotherapy Kidney Cancer Target therapy

COSMIC-313 trial

1679825974_171222-ESMO22-GU.png

In COSMIC-313 trial presented by Dr. Toni Choueiri, #cabozantinib (C) in combination with #nivolumab (N) and #ipilimumab (I) improved PFS...

Lung Cancer Bladder Cancer Breast Cancer CNS Cancers Colorectal Cancer COVID-19 Gastroesophageal Cancer Gastrointestinal Cancer Genomics/Genetics Geriatric Oncology Gynecologic Cancers Head and Neck Cancers Health-Care Policy Hepatobiliary Cancer Immunotherapy Integrative Oncology Kidney Cancer Legislation Leukemia Lymphoma Multiple Myeloma Neuroendocrine Tumors Palliative Care Pancreatic Cancer Prostate Cancer Sarcoma Skin Cancer Survivorship Symptom management Thyroid Cancer

FDA approval of bevacizumab biosimilar

1676463478_FDA-2.png

On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...

Kidney Cancer

IMmotion 010 trial

1676462777_Esmo-Kidney-cancer-2.png

In the IMmotion 010 study presented by Dr. Axel Bex, atezolizumab (anti-PD-L1) monotherapy was studied as adjuvant therapy in patients...

Kidney Cancer

PROSPER trial

1676462226_Esmo-Kidney-cancer-1.png

Perioperative #nivolumab did not improve relapse free survival (RFS) in early stage #RCC. This was illustrated in phase III PROSPER...

Latest Articles

Adjuvant in RCC
View More